Navigation Links
ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
Date:10/23/2007

isease or better per RECIST are eligible to receive repeat treatment.

Overall, the majority of adverse events and lab abnormalities have been mild to moderate and consistent with the known safety profiles of IL-21 and sorafenib. Dose limiting toxicities consisting of skin-related events have occurred in a total of two patients, including one in the 10 mcg/kg cohort (hand-foot syndrome), and one in the 50 mcg/kg cohort (rash).

11 patients have completed at least one 6-week treatment course, all of whom have gone on to receive repeat treatment, which has not been associated with increased toxicity. 10 of these 11 patients have had measurable disease per RECIST criteria, and all 10 have had a decrease in tumor mass as their best response on study, ranging from 18 to 33% per investigator assessment. Four patients had unconfirmed Partial Responses, with at least 30% decrease in tumor measurements per investigator assessment and 3 of these are still on treatment. Of the 11 patients who finished the first treatment course, nine continue to receive therapy on study, and two patients discontinued therapy due to disease progression.

Renal Cell Cancer

There will be an estimated 51,190 new cases of renal cell carcinoma in the U.S. in 2007. It is estimated that renal cell carcinoma will result in approximately 19,600 deaths in the U.S. in 2007. Renal cell carcinoma accounts for approximately 2% of cancers worldwide. There is a clear need for new and improved therapies for renal cell cancer.

IL-21 in Combination with Tyrosine Kinase Inhibitors

Because tyrosine kinase inhibitors (TKIs) such as Nexavar and Sutent(R) inhibit the growth of tumor cells, and IL-21 activates the immune system to target killing of tumor cells, the two therapies may provide additive or synergistic effects. Treatment with a TKI may make cancer cells more sensitive to natural killer or T cell mediated killing after activation with IL-21. Preclinical research conducted by
'/>"/>

SOURCE ZymoGenetics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... ANGELES , Jan. 23, 2015 A lot of ... best methods for treating  certain illnesses, injuries, or conditions. As ... replace previous treatment methods with ones that they consider to ... hernias, there is not one textbook method of treatment that ...
(Date:1/23/2015)... Jan. 23, 2015  The Partnership to Fight Chronic Disease (PFCD) released ... care leaders and a new study analyzing the impact of increased ... a nationwide coalition working to educate policy makers and the public ... Capitol was focused on how the Iowa ...
(Date:1/23/2015)... , Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... immune therapies for operable and inoperable solid tumor cancers, announced ... the 7 th Annual Phacilitate Immunotherapy Forum in ... at Phacilitate will take place on January 26 at 10:30 ...
Breaking Medicine Technology:No One-Size-Fits-All Remedy for Hernia Correction 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3
... Cardiac Dimensions, an early stage company focused on the ... mitral valve disease and congestive heart failure, announced today ... of the Company,s CARILLON® Mitral Contour System will be ... (ESC) on August 29, 2010 in Stockholm. ...
... Medical Corporation was recently named as a defendant, along with ... C.R. Bard in U.S. District Court in Arizona.  The suit ... 2002 related to prosthetic vascular grafts made of ePTFE (expanded ... regarding this patent for several years. The patent ...
Cached Medicine Technology:Cardiac Dimensions® Announces Presentation of 12-Month Follow-up Data of TITAN™ Trial at European Society of Cardiology Meeting 2Cardiac Dimensions® Announces Presentation of 12-Month Follow-up Data of TITAN™ Trial at European Society of Cardiology Meeting 3Cardiac Dimensions® Announces Presentation of 12-Month Follow-up Data of TITAN™ Trial at European Society of Cardiology Meeting 4Atrium Responds to Bard Suit 2
(Date:1/22/2015)... Oceanside,CA (PRWEB) January 22, 2015 For over 20 ... the Oceanside and Vista area has treated just about ... other personal injury circumstances. And for those same twenty-plus years, ... victims of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... Plainsboro, NJ (PRWEB) January 22, 2015 ... advocate and keynote speaker at the upcoming 32nd ... by ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , ... breast would have gone undetected if she had not ...
(Date:1/22/2015)... Jolla, Calif. (PRWEB) January 22, 2015 ... Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) ... for their leadership in advancing biotechnology, biomedical science, ... Bonilla and Olsen each received the “2014 Life ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and easy ... treat specific body parts and muscle groups. , IsoComforter, ... use patented cold therapy machine with the innovative IsoTube design ... injuries. IsoComforter has become the industry leader in cold ...
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... ... eye surgeons worldwide and hindsight could soon be 20/10. He believes that vision beyond 20/20 is ... of their patients. , ... 2010 -- 20/20 vision has been the hallmark of perfect vision. That Bar is about to ...
... ... company CTW, Inc. of Mississippi and Massachusetts-based medical device manufacturer Tegra Medical to join ... ... private equity firm based in Boston, MA, is pleased to announce its majority investment ...
... ... anesthesiologists to solve. Patients must wake up quickly and able to go home pain, nausea and ... standard of care for patient safety in outpatient surgery,” says Dr. F. Don Parsa, Chief of ... (PRWEB) ...
... , LOS ANGELES , ... California,s three regional Hospital Associations, and the National Health Foundation, ... 6 million dollar effort to improve the quality and consistency ... the launch of Patient Safety First... a California Partnership ...
... Jan. 19 , Disaster Statistics ... 100,000 3 million people displaced or otherwise impacted by earthquake (Population ... , Conditions in Port-au-Prince ... across 243 different locations in Port-au-Prince . In addition, many ...
... ... to reach out to prospective patients and to describe the treatments that are available at ... a before-and-after photo gallery, video documentaries, and an online consultation form, the new website provides ... ...
Cached Medicine News:Health News:20/10 Vision in the Year 2010: Is "HD Vision" Beyond 20/20 a Reality? 2Health News:20/10 Vision in the Year 2010: Is "HD Vision" Beyond 20/20 a Reality? 3Health News:Riverside Partners Announces Acquisition of CTW, Inc. and Partnership with Tegra Medical 2Health News:Riverside Partners Announces Acquisition of CTW, Inc. and Partnership with Tegra Medical 3Health News:Riverside Partners Announces Acquisition of CTW, Inc. and Partnership with Tegra Medical 4Health News:Michael Jackson Propofol Expert, Barry Friedberg MD, Spoke at Pan Pacific Surgery Meeting 2Health News:Anthem Blue Cross Partners With California Regional Hospital Associations and The National Health Foundation To Launch an Historic Three-Year Statewide Patient Safety Collaborative 2Health News:Anthem Blue Cross Partners With California Regional Hospital Associations and The National Health Foundation To Launch an Historic Three-Year Statewide Patient Safety Collaborative 3Health News:Anthem Blue Cross Partners With California Regional Hospital Associations and The National Health Foundation To Launch an Historic Three-Year Statewide Patient Safety Collaborative 4Health News:Anthem Blue Cross Partners With California Regional Hospital Associations and The National Health Foundation To Launch an Historic Three-Year Statewide Patient Safety Collaborative 5Health News:World Vision Situation Update: More Aid Reaching Many Survivors, but Conditions Remain Dire 2Health News:World Vision Situation Update: More Aid Reaching Many Survivors, but Conditions Remain Dire 3Health News:A Top Cosmetic Dentistry Practice in Central New Jersey Announces Launch of New, State-of-the-Art Website 2Health News:A Top Cosmetic Dentistry Practice in Central New Jersey Announces Launch of New, State-of-the-Art Website 3Health News:A Top Cosmetic Dentistry Practice in Central New Jersey Announces Launch of New, State-of-the-Art Website 4
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...
... special order products are offered as 1-piece ... lengths. The modular instruments may be customized ... such as ratchets, insulation and flush ports. ... stock. Customer specifications may affect delivery times. ...
... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...
Medicine Products: